DAREON™-7: A study to test how well different doses of BI 764532 in addition to chemotherapy are tolerated by people with advanced neuroendocrine cancers

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505870-13-00

Acronym

1438-0007

Enrollment

Registered

2023-11-20

Start date

2024-01-11

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extra-pulmonary neuroendocrine carcinoma (epNEC), Neuroendocrine carcinoma (NEC) with unknown primary site, pulmonary Large cell neuroendocrine carcinoma (LCNEC)

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Belgium, France, Germany, Netherlands, Spain, Sweden

Outcome results